Compare Upstart Holdings Inc (UPST) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Upstart Holdings Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Upstart Holdings Inc trades at $29.91 (market cap $2.94B), while Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 45.2× Upstart Holdings Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Upstart Holdings Inc nearer its low. Which is the better fit depends on your goals.
| UPST | VRTX | |
|---|---|---|
Market Cap | $2.94B | $132.79B |
Sector | Financials | Health |
52-Week High | $73.76 | $529.65 |
52-Week Low | $24.22 | $376.62 |
Enterprise Value | — | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Upstart (UPST) trades at $31.09, up 4.64% on the day, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue growth of 42% year-over-year and a return to GAAP profitability, with loan originations surging 50%. However, it has missed EPS expectations for three consecutive quarters. The stock is supported by a consensus analyst price target of $47.20, implying significant upside, but faces headwinds from high interest rates and competitive pressures.
The outlook is mixed: strong loan growth and AI-driven underwriting improvements offer growth potential, but recent earnings misses, a high P/E ratio of 59.79, and negative operating cash flow in 2025 pose risks. Investor sentiment is cautiously optimistic, with 45% of analysts rating it a Buy, though volatility from macroeconomic factors remains a key concern for shareholders.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
